Two women discussing efruxifermin, or EFX, in front of a whiteboard

Publications & posters

Our drug R&D is supported by scientific research published by the Akero team, our collaborators, and by external experts.

PUBLICATIONS SHOULD BE DELIVERED SEPARATELY USING A SPREADSHEET PROGRAM (EXCEL OR SHEETS)

Filter

Jun 2023 | From Akero Therapeutics

Noninvasive tests of liver injury, inflammation and fibrosis are improved by efruxifermin and correlate with histological improvements in patients with F2-F3 NASH: secondary analysis of Ph2b HARMONY study

Jörn M. Schattenberg, Juan Frias, Guy Neff, Gary A Abrams, Jeannie Lucas, William Sanchez, Sudhanshu Gogia, Muhammed Y. Sheikh, Cynthia Behling, Pierre Bedossa, Lan Shao, Erica Fong, Brittany de Temple, Doreen Chan, Reshma Shringarpure, Erik J Tillman, Timothy Rolph, Andrew Cheng, Kitty Yale, and Stephen A Harrison 2023 International Liver Congress (EASL)

Jun 2023 | From Akero Therapeutics

Characterization of the Patterns of Resolution of Histopathology After Efruxifermin Treatment of Patients with NASH Fibrosis (F2/3) for 24 Weeks

Cynthia Behling, Pierre Bedossa, Lan Shao, Erica Fong, Brittany de Temple, Doreen Chan, Reshma Shringarpure, Erik J Tillman, Timothy Rolph, Andrew Cheng, Kitty Yale, and Stephen A Harrison 2023 International Liver Congress (EASL)

Mar 2023 | From Akero Therapeutics

Efruxifermin, a long-acting, bivalent FGF21 analog, normalized noninvasive measures of liver injury, fibrosis, and metabolic health in patients with NASH and F2/F3 fibrosis over 24 weeks

Doreen Chan, Erik J Tillman, Reshma Shringarpure, Andrew Cheng, Stephen A Harrison, Kitty Yale, Tim Rolph Keystone Symposium: Metabolic and Molecular Mechanisms of NAFLD/NASH

Mar 2023 | From Akero Therapeutics

Efruxifermin, a bivalent Fc-FGF21 analog, demonstrated improved biophysical and pharmacological engagement with live cells compared to monovalent FGF21 analogs

Erik J Tillman, Sina Bondza, Louben Dorval, Anna Boström, Tim Rolph Keystone Symposium: Metabolic and Molecular Mechanisms of NAFLD/NASH

Nov 2022 | From Akero Therapeutics

Efruxifermin, a bivalent Fc-FGF21 analog, demonstrates improved biophysical and pharmacological engagement with live cells compared to monovalent FGF21 analogs

Erik J Tillman, Sina Bondza, Louben Dorval, Anna Boström, Tim Rolph The Liver Meeting 2022 (AASLD)

Aug 2022 | From Akero Therapeutics

Normalization of liver fat by efruxifermin is associated with improved liver, adipose tissue, and whole-body metabolic health

Erik Tillman Keystone Symposium on Adipose Tissue and Metabolic Health

Aug 2022 | From Akero Therapeutics

A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis

Stephen A. Harrison, Peter J. Ruane, Bradley Freilich, Guy Neff, Rashmee Patil, Cynthia Behling, Chen Hu, Reshma Shringarpure, Brittany de Temple, Erica Fong, Erik J. Tillman, Timothy Rolph, Andrew Cheng, Kitty Yale JHEP Reports

Jun 2022 | From Akero Therapeutics

Efruxifermin treatment improved histopathology and non-invasive markers of liver injury and fibrogenesis in NASH patients across PNPLA3 genotypes: a post hoc analysis of the Ph2a BALANCED study

Erik J Tillman, Reshma Shringarpure, Guy Neff, Rashmee Patil, Bradley Freilich, Cynthia Behling, Erica Fong, Brittany de Temple, Kitty Yale, Stephen A Harrison, Tim Rolph The International Liver Congress™ 2022 (EASL)

Close up of multichannel micropipette filling four small blue centrifuge tubes

We have developed a comprehensive clinical program to evaluate EFX as a potential treatment for MASH.

View Our Pipeline